Other Events ·
Harvard Bioscience releases investor presentation highlighting $87M FY25 revenue and debt refinancing
HBIOHarvard Bioscience Inc
Harvard Bioscience filed an 8-K to distribute its November 2026 corporate slide presentation. The filing provides a comprehensive overview of the company's strategic initiatives, including Project Viking manufacturing consolidation targeting $3 million in adjusted EBITDA improvements by FY2027 and $4 million annually thereafter. Financial highlights include $87 million in FY2025 revenue, 58% adjusted gross margin, and $8 million in adjusted EBITDA. The company also details a December 2025 debt refinancing that extended maturities through 2029 and unlocked approximately $3 million in annual cash savings. Management is guiding for 3-5% revenue growth in FY2026 with an adjusted EBITDA margin of 57-59%. Harvard Bioscience builds tools that power translational research across drug discovery and preclinical development.